MYGN Q4 2025 Earnings — Myriad Genetics, Inc. Revenue & Financial Results | Market Cap Arena

MYGNMyriad Genetics, Inc.

$487M

Q4 2025 Earnings

Healthcare Medical - Diagnostics & Research

Income Statement

Revenue

$210M-0.4% YoY

Gross Profit

$147M70.0% margin

Operating Income

$120M57.2% margin

Net Income

-$8M-3.8% margin

EPS (Diluted)

$-0.08

QoQ Revenue Growth

+2.0%

Cash Flow

Operating Cash Flow

$11M

Free Cash Flow

$11M

Stock-Based Comp.

$0

Balance Sheet

Total Assets

$707M

Total Liabilities

$339M

Stockholders' Equity

$368M

Cash & Equivalents

$150M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$210M	$211M	-0.4%
Gross Profit	$147M	$151M	-2.7%
Operating Income	$120M	-$39M	+407.7%
Net Income	-$8M	-$43M	+81.4%

Geographic Segments

UNITED STATES

$197M94%

Non-US

$13M6%